Liu Honggai, Yue Qingfen, He Shehong
Department of Gynaecology, Luoyang Central Hospital, Zhengzhou University, China.
Department of Gynaecology, Luoyang Central Hospital, Zhengzhou University, China.
Life Sci. 2017 Nov 15;189:96-105. doi: 10.1016/j.lfs.2017.09.026. Epub 2017 Sep 20.
Ovarian cancer is one of most common malignancies in women and is associated with high reoccurrence rate and poor prognosis. This study is designed to investigate the anti-tumor effects of amentoflavone (AF), one of the major active ingredients of S. tamariscina, against ovarian cancer.
Human ovarian cancer cell lines SKOV3 and OVCAR-3 were used in this study. The effect of AF on cell viability was examined by CCK-8 assay. Cell apoptosis and cell cycle distribution was determined by flow cytometry. ROS generation was detected using fluorescent staining. Expression of signaling molecules was determined by western blots. Xenograft model was established to evaluate the therapeutic efficacy of AF in vivo.
Our results showed that AF could significantly suppress cell proliferation, induce apoptosis and block cell cycle progression. Mechanistically, downregulation of S-phase kinase protein 2 (Skp2) by AF contributed to its anti-tumor effect against ovarian cancer. Furthermore, our results showed that AF repressed the expression of Skp2 through ROS/AMPK/mTOR signaling. The anti-tumor effect of AF against ovarian cancer was also confirmed in a xenograft animal model.
Overall, our present findings highlighted the potential of AF in the treatment of ovarian cancer. Moreover, our study also provided a new elucidation regarding the anti-tumor mechanisms of AF.
卵巢癌是女性最常见的恶性肿瘤之一,复发率高且预后较差。本研究旨在探讨卷柏主要活性成分之一穗花杉双黄酮(AF)对卵巢癌的抗肿瘤作用。
本研究采用人卵巢癌细胞系SKOV3和OVCAR-3。通过CCK-8法检测AF对细胞活力的影响。采用流式细胞术测定细胞凋亡和细胞周期分布。利用荧光染色检测活性氧(ROS)的产生。通过蛋白质免疫印迹法测定信号分子的表达。建立异种移植模型以评估AF在体内的治疗效果。
我们的结果表明,AF可显著抑制细胞增殖、诱导凋亡并阻断细胞周期进程。机制上,AF下调S期激酶相关蛋白2(Skp2)有助于其对卵巢癌的抗肿瘤作用。此外,我们的结果表明,AF通过ROS/AMPK/mTOR信号通路抑制Skp2的表达。AF对卵巢癌的抗肿瘤作用在异种移植动物模型中也得到了证实。
总体而言,我们目前的研究结果突出了AF在治疗卵巢癌方面的潜力。此外,我们的研究还为AF的抗肿瘤机制提供了新的阐释。